Search

Cytokinetics Inc

Chiusa

SettoreSettore sanitario

87.65 2.31

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

84.38

Massimo

86.82

Metriche Chiave

By Trading Economics

Entrata

-23M

-206M

Vendite

1.6M

19M

EPS

-1.67

Margine di Profitto

-1,064.485

Dipendenti

673

EBITDA

11M

-169M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+25.29% upside

Dividendi

By Acuity

Utili prossimi

6 ago 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

3.6B

12B

Apertura precedente

85.34

Chiusura precedente

87.65

Notizie sul Sentiment di mercato

By Acuity

50%

50%

164 / 342 Classifica in Healthcare

Cytokinetics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

6 lug 2026, 23:41 UTC

Correlated Moves
Social Media
News

Micron Technology shares are lower in after-market trading, reflecting broader market pressures and concerns over a potential memory oversupply by 2028.

6 lug 2026, 23:31 UTC

Correlated Moves
News
Social Media

Microsoft Corp announced layoffs of about 4,800 employees, primarily in its Xbox division. Shares are lower in after-market trading following the news.

6 lug 2026, 23:26 UTC

Correlated Moves
News

Analog Devices Inc. is advancing in after-market trading, driven by a rebound in the semiconductor sector and bullish updates from UBS and Goldman Sachs.

6 lug 2026, 23:02 UTC

Social Media
News

Vertex Pharmaceuticals shares declined in after-market hours following its $10 billion acquisition of Crinetics Pharmaceuticals at $85 per share, expected to close in 2026.

6 lug 2026, 20:51 UTC

News
Correlated Moves

Invesco CurrencyShares Euro Trust is gaining in after-market trading, influenced by comments from Federal Reserve Governor Christopher Waller on monetary policy complexities.

6 lug 2026, 20:07 UTC

News

Verisign shares are higher amid reported $1.1 billion in free cash flow, though concerns linger over AI advancements and upcoming contract renewals.

6 lug 2026, 20:07 UTC

News
Social Media

Netflix Inc faces engagement issues, prompting bearish investor sentiment. The stock is trading lower amid concerns ahead of its upcoming earnings report.

6 lug 2026, 20:07 UTC

Social Media
News
Macro Event

PayPal Holdings Inc. shares are lower as recent ISM Services data showed a slowdown in growth, with the PMI declining from the previous month.

6 lug 2026, 20:07 UTC

Correlated Moves
News

Ethereum is advancing, supported by Tom Lee's BitMine purchasing $74 million in the asset, raising their total holdings to 5,742,237 ETH.

6 lug 2026, 20:07 UTC

Correlated Moves
News

Bitcoin trades higher, recovering from earlier lows, amid stable cryptocurrency market conditions and concerns over inflation and interest rates. Current price is $61,750.

6 lug 2026, 20:07 UTC

News
Correlated Moves

Bitcoin's value has risen since Sunday, reaching around $61,750. This increase occurs amid broader cryptocurrency market weakness and concerns over inflation and interest rates.

6 lug 2026, 20:07 UTC

Social Media
News

Adobe Inc. shares are lower amid scrutiny of first-quarter results and competitive pressures from Canva and Figma, with support noted at $215.

6 lug 2026, 20:07 UTC

News
Social Media

Apple Inc. shares are higher following an extended partnership with Broadcom for custom chips through 2031 and the reintroduction of card payments in India.

6 lug 2026, 20:06 UTC

Event
News

Cisco Systems Inc shares are higher today as the company went ex-dividend, distributing $0.42 per share, amid positive analyst upgrades.

6 lug 2026, 20:06 UTC

News

Ulta Beauty Inc. shares are lower amid declines in the Other Specialty Retail sub-sector and broader market weakness, trading near the bottom of its one-month range.

6 lug 2026, 20:06 UTC

Social Media
News

Scotiabank upgraded Check Point Software to Sector Outperform, setting a price target of $185, following its 2025 ESG Report release. Shares are higher since Thursday's close.

6 lug 2026, 20:06 UTC

News

Cintas Corp shares are lower today, continuing a broader market decline since Thursday. The stock peaked early but has trended downward since.

6 lug 2026, 20:06 UTC

News

Cadence Design Systems reported first-quarter revenue of $1.474 billion, an 18.7% year-over-year increase, and a record backlog of $8 billion. Shares are trading higher.

6 lug 2026, 20:06 UTC

News

Amgen shares are lower as Cantor Fitzgerald maintains a Neutral rating with a $350 price target, reflecting cautious investor sentiment amid recent volatility.

6 lug 2026, 20:04 UTC

News
Social Media

Tesla shares are higher today, fueled by strong second-quarter delivery figures and the positive reception of its robotaxi service in Miami.

6 lug 2026, 20:02 UTC

News

Align Technology shares are higher today following a rating upgrade to "strong-buy" from Wall Street Zen, despite a downgrade from Weiss Ratings.

6 lug 2026, 20:02 UTC

News

Mondelez International shares are lower amid weakness in the Packaged Foods & Meats sector. The stock remains near the lower end of its one-month trading range.

6 lug 2026, 20:02 UTC

News
Social Media
Correlated Moves

Qualcomm's stock rises as Nvidia's CEO endorses its AI tech and Bernstein raises its price target. A partnership with Meta also boosts investor interest.

6 lug 2026, 20:02 UTC

News
Social Media

Gilead Sciences is trading lower amid a Biotechnology sector decline, despite HSBC's upgrade to Buy and a raised price target of $155.

6 lug 2026, 20:02 UTC

Macro Event
News

J B Hunt shares decline after Morgan Stanley downgraded the stock to Underweight, raising the price target to $200 from $190 amid sector concerns.

6 lug 2026, 19:57 UTC

News
Social Media

Berkshire Hathaway has tripled its stake in Alphabet, boosting investor sentiment. Alphabet's inclusion in the Dow Jones further underscores its growth potential.

6 lug 2026, 19:56 UTC

News

Natural gas is trading higher today, maintaining an upward trajectory above its 20-day moving average. ProShares Ultra Bloomberg Natural Gas has gained since Thursday's close.

6 lug 2026, 19:53 UTC

News

Charter Communications Inc is declining amid low demand for services and stagnant returns on capital. Analysts rate the stock as "Reduce," reflecting a cautious outlook.

6 lug 2026, 19:52 UTC

Social Media
News

Evercore ISI raised its price target on Illumina to $200, maintaining an Outperform rating. Shares are trading higher amid positive sentiment and social media discussions.

6 lug 2026, 19:51 UTC

Social Media
News

Bank of America upgraded T-Mobile US Inc to Buy, maintaining a $220 price target, citing overstated competition concerns and the company's urban market dominance.

Confronto tra pari

Modifica del prezzo

Cytokinetics Inc Previsione

Obiettivo di Prezzo

By TipRanks

25.29% in crescita

Previsioni per 12 mesi

Media 107.21 USD  25.29%

Alto 140 USD

Basso 83 USD

Basato su 15 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Cytokinetics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

15 ratings

13

Acquista

2

Mantieni

0

Vendi

Sentiment

By Acuity

164 / 342 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
help-icon Live chat